The obesity drug market is heating up fast, and Pfizer just made a major play. Their acquisition of Metsera for up to $7.3 billion shows how serious big pharma is getting about capturing share in what analysts project will be a $150 billion market by the early 2030s.
What makes this deal interesting is the timing. Pfizer had to discontinue their own oral GLP-1 program, so they’re essentially buying their way back into the game. Metsera brings two promising candidates to the table: MET-097i (a GLP-1 agonist) and MET-233i (an amylin analog that could potentially be dosed monthly). The monthly dosing angle is particularly compelling from a competitive standpoint.
Meanwhile, Roche is pushing their CT-388 into Phase 3 trials as part of their plan to become a top-3 player by 2030. The space is getting crowded, but there’s clearly room for multiple winners given the massive patient population and unmet medical need.
For industry watchers, this reinforces that we’re still in the early innings of the metabolic revolution. Companies that can crack the code on convenience, efficacy, and tolerability will likely see outsized returns.
